Re: AACR 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR 2019

in response to

Re: AACR 2019

narmac

posted on Feb 28, 2019 01:48PM

Thanks Narmac. I'm not sure what their clinical plans are for ZEN-3309. It might be a back up clinical molecule. From the news release I linked to earlier, it clearly indicates that the Pfizer/Breast Cancer trial was going to be with ZEN-3694 with no mention of ZEN-3309.